<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405416</url>
  </required_header>
  <id_info>
    <org_study_id>chenxp006</org_study_id>
    <secondary_id>2012ZX10002016-004</secondary_id>
    <nct_id>NCT02405416</nct_id>
  </id_info>
  <brief_title>Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping</brief_title>
  <official_title>A Prospective Randomized Controlled Trial to Compare Infrahepatic Inferior Vena Cava Clamping With Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping in Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to compare infrahepatic inferior vena cava clamping (IIVCC) with
      selective hepatic vascular exclusion (SHVE) involving the portal triad clamping (PTC) in
      complex cirrhotic liver resection. One group will receive IIVCC plus PTC, while an another
      equivalent group patients will be operated using SHVE and PTC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraoperative blood loss is significantly associated with clinical outcomes of patients
      undergoing hepatectomy. There have been various hepatic vascular control techniques,
      including infrahepatic inferior vena cava clamping (IIVCC) and selective hepatic vascular
      exclusion (SHVE).The propose of this study is to compare these two surgical techniques
      combined with the portal triad clamping (PTC) in hepatic cirrhotic patients. All patients
      being performed hepatectomy at the center are scanned according to inclusion and exclusion
      criteria. After intraoperative exploration, patients are randomized into two interventional
      groups. PTC, IIVCC or SHVE is performed at the specified timepoint in liver parenchymal
      transection in two different groups. All data are collected prospectively.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>blood loss from incision to closure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalized transection-related blood loss</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Intraoperative blood loss normalized by transection surface area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of infrahepatic inferior vena cava or selected hepatic vein dissection</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Time cost of dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations of intraoperative infrahepatic inferior vena cava pressure or hepatic vein pressure</measure>
    <time_frame>Intraoperative period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop of hemoglobin level</measure>
    <time_frame>Drop of hemoglobin level will be measured during liver parenchymal transection period(neither the specific time point nor expected average could be given prospectively because of different surgical situations)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postrecovery of liver function</measure>
    <time_frame>postoperative days 1, 3, 5, 7</time_frame>
    <description>Liver function evaluation is composite of liver enzyme ，total bilirubin, prothrombin activity, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postrecovery of renal function</measure>
    <time_frame>postoperative days 1, 3, 5, 7</time_frame>
    <description>Renal function evaluation is composite of blood urea nitrogen, creatinine, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity of postoperative complications</measure>
    <time_frame>90 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>90 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Neoplasms</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>IIVCC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHVE group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infrahepatic inferior vena cava clamping</intervention_name>
    <description>Infrahepatic inferior vena cava is clamped in hepatectomy.</description>
    <arm_group_label>IIVCC group</arm_group_label>
    <other_name>IIVCC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective hepatic vascular exclusion</intervention_name>
    <description>Selected major hepatic vein is clamped in hepatectomy.</description>
    <arm_group_label>SHVE group</arm_group_label>
    <other_name>SHVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Portal triad clamping</intervention_name>
    <description>Portal triad are clamped in hepatectomy.</description>
    <arm_group_label>IIVCC group</arm_group_label>
    <arm_group_label>SHVE group</arm_group_label>
    <other_name>PTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. either male or female, older than 18 (include 18).

          2. tumors oppress or be in close proximity to one or more of major hepatic veins.

          3. the maximum diameter of tumor ≥ 5cm, number of lesions ≤ 3 and should be in same liver
             lobe if multiple lesions exit.

          4. preoperative liver function assessment: Child-Pugh classification is A or B.

          5. preoperative laboratory test: blood platlet count ＞ 100×10^9/l, prothrombin activity ＞
             60%.

          6. liver cirrhosis.

        Exclusion Criteria:

          1. contraindication for surgery,e.g.severe disorders of circulation, respiratory or renal
             system.

          2. extrahepatic metastasis in patients with malignancy or tumor invasion of portal vein,
             hepatic vein, bile duct or inferior vena cava.

          3. hepatectomy accompanied with other organs resection(e.g. bile duct, intestine,
             pancreas or stomach)

          4. regular hepatectomy.

          5. tumors located in the left lateral lobe of liver.

          6. previous hepatectomy.

          7. pregnancy or lactation.

          8. refusal to participate this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Chen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoping Chen, M.D.</last_name>
    <phone>+86 27 83662851</phone>
    <email>chenxp@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Wu, M.M.</last_name>
    <phone>+8618986136006</phone>
    <email>dr_wuchao@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Chen, M.D.</last_name>
      <phone>+86 27 83662851</phone>
      <email>chenxp@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chao Wu, M.M.</last_name>
      <phone>+86 18986136006</phone>
      <email>dr_wuchao@hust.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Chairman and Professor of Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Blood Loss</keyword>
  <keyword>Haemorrhage</keyword>
  <keyword>Vascular Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

